Eleni Efstathiou, Professor of Medicine and Genitourinary Oncology Chair at OHSU Knight Cancer Institute, shared a post on LinkedIn:
“Another win for precision medicine in prostate cancer!
Molecular/Genomic testing is a requirement for good clinical practice! No excuses no delays and no patient left behind.
It takes a lot of such wins to stack and move the needle in our field and they are coming.”
PrTK03 Trial: Aglatimagene Besadenovec Plus Radiotherapy in Localized Prostate Cancer
